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Introduction {#sec1}
============

In 2003, severe acute respiratory syndrome (SARS) spread rapidly from China throughout Asia to Canada ([@bib50]). Most patients who died of SARS developed acute respiratory distress syndrome (ARDS) ([@bib27])---the most severe form of acute lung injury (ALI) ([@bib48]). ARDS was also the cause of death in millions of people during the Spanish Influenza pandemic ([@bib44]). Recently, H5N1 avian influenza virus infections have spread through the world primarily infecting poultry and migratory birds. The reported death rates of H5N1 avian influenza infections in humans are ∼50%, prompting the fear that H5N1 might cause a worldwide pandemic ([@bib4], [@bib49]).

The high lethality of H5N1 or SARS infections as well as their economic and social impact makes it paramount to explore common disease mechanisms and novel therapeutic targets of ARDS. Moreover, many viruses including H5N1 mutate readily and produce resistant strains that are no longer controlled by vaccines or antiviral drugs. The pathology of ARDS in SARS-coronavirus ([@bib27]) and H5N1 avian influenza virus infections ([@bib4], [@bib38]) is characterized by accumulation of inflammatory cells, edema formation, and a marked increase in cytokines. The same clinical syndrome of acute lung failure is observed in multiple other pathogenic conditions including sepsis, gastric acid aspiration, or pulmonary infections with Anthrax spores ([@bib18], [@bib13]). Similar ARDS symptoms can be observed in multiple species ranging from birds, rodents, tigers, and primates to humans. Given the common pathology, we wondered whether there might be a conserved injury pathway for ARDS.

Results {#sec2}
=======

TLR4 Is a Susceptibility Gene for ALI {#sec2.1}
-------------------------------------

To identify endogenous genes that control the severity of ALI, we tested inbred mouse strains for their propensity to develop ALI in response to acid aspiration, a model that recapitulates the acute phase of human ARDS ([@bib20], [@bib35]). Acid aspiration in mice results in rapid impairment of lung function as determined by increased lung elastance, a measure of the change in pressure achieved per unit change in volume, representing the stiffness of the lungs, decreased blood oxygenation, and alveolar wall thickening, bleeding, inflammatory cell infiltration, and formation of hyaline membranes ([Figures S1](#app2){ref-type="sec"}A--S1C available online). The severity of acid-induced ALI was comparable among various inbred mouse strains with one exception: C3H/HeJ mice exhibited reduced lung elastance. Moreover, C3H/HeJ mice exhibited better blood oxygenation and reduced inflammation ([Figures S1](#app2){ref-type="sec"}A--S1C).

C3H/HeJ mice exhibit resistance to a lipopolysaccharide (LPS) challenge due to a mutation in the intracellular domain of Toll-like receptor 4 (TLR4) (Tlr4^Lps-d^) that interferes with TLR4 signaling ([@bib39]). To test whether this TLR4 mutation might be involved in ALI severity, we assessed acid-induced ALI in C3H/HeOuJ mice, a C3H-congenic mouse strain that expresses wild-type (WT) TLR4. The resistance to ALI of C3H/HeJ mice was lost in C3H/HeOuJ mice ([Figures S1](#app2){ref-type="sec"}A--S1D). To confirm that TLR4 determines disease severity, we triggered acid-mediated ALI in *tlr4^−/−^* mice ([@bib16]). Genetic inactivation of *tlr4* markedly attenuated ALI as determined by improved lung elastance ( [Figure 1](#fig1){ref-type="fig"}A), reduced edema formation ([Figure 1](#fig1){ref-type="fig"}B), and ameliorated histological changes ([Figure 1](#fig1){ref-type="fig"}C). Bone marrow chimeras showed that the severity of ALI is controlled by TLR4 expression on hematopoietic cells ([Figures 1](#fig1){ref-type="fig"}D--1F). Lung pathology were not affected in *tlr3* ([@bib51]) or *tlr9* ([@bib15]) mutant mice ([Figures S2](#app2){ref-type="sec"}A and S2B). These data identify TLR4 as a susceptibility gene for ALI.Figure 1TLR4 Is a Susceptibility Gene for Acute Lung Injury(A) Changes in lung elastance after acid or saline treatment in WT and *tlr4*^−/−^ mice. n = 8--10 for acid-treated groups, n = 6 for saline-treated groups. ^∗∗^p \< 0.01 for the whole time course.(B) Lung edema formation after acid or saline treatment. ^∗^p \< 0.05.(C) Lung histopathology. H&E staining. Original magnifications × 200.(D) Lung elastance after acid treatment of WT mice transplanted with WT bone marrow (BM) (WT BM → WT), WT mice receiving *tlr4*^−/−^ BM (*tlr4*^−/−^ BM → WT), *tlr4*^−/−^ mice transplanted with WT BM (WT BM → *tlr4*^−/−^), and *tlr4*^−/−^ mice receiving *tlr4*^−/−^ BM (*tlr4*^−/−^ BM → *tlr4*^−/−^). n = 6 for each group.(E) Lung edema formation and (F) lung histopathology 3 hr after acid injury in WT BM → WT, *tlr4*^−/−^ BM → WT, WT BM → *tlr4*^−/−^, and *tlr4*^−/−^ BM → *tlr4*^−/−^ chimeras.In (D) and (E), ^∗^p \< 0.05 comparing WT BM → WT or WT BM → *tlr4*^−/−^ mice. n = 6 for each group. H&E staining. Original magnifications × 200. Data in (A), (B), (D), and (E) are mean values ± SEM.

Acute Lung Injury Is Mediated via TLR4-TRIF-TRAF6-NF-κB Signaling {#sec2.2}
-----------------------------------------------------------------

TLR4 stimulation is relayed to cellular responses via different adaptors such as MyD88 and TRIF ([@bib2]). Surprisingly, genetic deletion of *myd88* ([@bib1]) had no apparent effect on the severity of ALI ([Figures S2](#app2){ref-type="sec"}C and S2D). In contrast, *trif^−/−^* mice ([@bib51]) exhibited markedly improved lung function ( [Figure 2](#fig2){ref-type="fig"}A), lung pathology ([Figure 2](#fig2){ref-type="fig"}B), and lung edema ([Figure S3](#app2){ref-type="sec"}A). TRIF signals either through IKK-ɛ and activation of IRF3 or via TRAF6-mediated NF-κB activation ([@bib43]). To dissect the TLR4-TRIF activation pathway, we conducted experiments using *irf3* and *traf6* knockout mice. Deletion of *irf3* ([@bib42]) did not show a significant change in acid-mediated ALI ([Figures S2](#app2){ref-type="sec"}E and S2F). We next generated myeloid cell-specific *traf6* mutant mice using Lys-Cre-mediated deletion of a TRAF6^flox/flox^ allele (TRAF6^MC-KO^). Deletion of TRAF6 was confirmed in cultured bone marrow-derived macrophages ([Figure 2](#fig2){ref-type="fig"}C). Inactivation of TRAF6 in TRAF6^MC-KO^ mice resulted in alleviation of ALI ([Figures 2](#fig2){ref-type="fig"}D, 2E, and [S3](#app2){ref-type="sec"}B). To determine whether mutations of TLR4, TRIF, or TRAF6 affect NF-κB activation, we performed in situ signaling experiments to detect nuclear accumulation of Ser276-phosphorylated NF-κBp65 indicative of NF-κB activation ([@bib46]). Whereas acid aspiration triggered NF-κBp65 activation in WT and *myd88^−/−^* mice, much less nuclear NF-κBp65 translocation occurred in lungs from *tlr4^−/−^*, *trif^−/−^,* or TRAF6^MC-KO^ mice ([Figure 2](#fig2){ref-type="fig"}F). NF-κB activation was largely restricted to macrophages. Taken together, our genetic results identify TLR4-TRIF-TRAF6-NF-κB as a key signaling pathway that links acid injury to the severity of ALI.Figure 2TRIF-TRAF6-NFκB-Cytokine Signaling Mediates the Severity of Acid Aspiration-Induced Acute Lung Injury(A) Lung elastance after acid or saline treatment of WT and *trif*^−/−^ mice. n = 6--10 for acid-treated groups, n = 4 for saline-treated groups. ^∗∗^p \< 0.01 for the whole time course.(B) Reduced inflammation and hyaline membrane formation in acid-treated *trif*^−/−^ mice. H&E staining. Original magnifications × 200.(C) TRAF6 protein expression in bone marrow macrophages isolated from Lys-Cre(−) TRAF6^flox/flox^ (TRAF6^MC-WT^) and Lys-Cre(+) TRAF6^flox/flox^ (TRAF6^MC-KO^) mice. β-actin protein is shown as control. Data from two different mice (1, 2) are shown for each genotype.(D) Changes in lung elastance in TRAF6^MC-WT^ (n = 6) and TRAF6^MC-KO^ mice (n = 4) following acid aspiration. ^∗^p \< 0.05 for the whole time course.(E) Reduced inflammatory cell infiltration, bleeding, and hyaline membrane formation in acid-treated TRAF6^MC-KO^ mice. H&E staining. Original magnifications × 200.(F) Immunolocalization of Ser276-phosphorylated NFκBp65 in lung tissue of saline-treated control WT mice and acid-treated WT, *myd88*^−/−^*tlr4*^−/−^, *trif*^−/−^, and TRAF6^MC-KO^ mice. Note the accumulation of phosphorylated NFκBp65 in nuclei of macrophages (red arrows) in acid-treated WT and *myd88*^−/−^ mice, which is absent in lung macrophages (black arrows) from acid-treated *tlr4*^−/−^, *trif*^−/−^, and TRAF6^MC-KO^ mice. Original magnifications × 400.(G) IL-6 levels in lung tissue after acid treatment in WT Balb/c, WT BL6, control TRAF6^MC-WT^ (wild-type), *tlr4*^−/−^ (Balb/c background), *tlr9*^−/−^ (BL6 background), *tlr3*^−/−^ (BL6), *myd88*^−/−^ (Balb/c) *trif*^−/−^ (BL6), *irf3*^−/−^ (BL6), and TRAF6^MC-KO^ mice. IL-6 levels were determined by whole lung tissue ELISA. n = 5--8 animals for each group. ^∗^p \< 0.05.(H) Lung elastance after acid treatment in interleukin-6 mutant (*il-6*^−/−^) and control WT mice. n = 5--6 each group. ^∗^p \< 0.05.(I) Improved lung histopathology in acid-treated *il-6*^−/−^ mice. H&E staining. Original magnifications × 200. Lungs were analyzed 3 hr after treatment.(J) Schematic diagram depicting the role of TLR4 in ALI. Data in (A), (D), (G), and (H) are mean values ± SEM.

IL-6 Mediates Acute Lung Injury {#sec2.3}
-------------------------------

Local cytokine production at the site of injury is one of the hallmarks of ALI ([@bib28]). The molecular basis of how such cytokine storms are mediated by local injury and whether such injury-released cytokines actually contribute to disease severity of ARDS are still unknown. To examine whether TLR4 signaling may be involved in local cytokine, we performed multiple cytokine arrays from normal lungs and lung tissue following acid aspiration. The cytokines IL-6, IL-1β, and KC (IL-8) were upregulated by acid treatment in WT mice, but we failed to observe upregulation of TNFα, IL-2, IFN-γ, IL-1α, IL-12p40, IL-12p70, IL-17, RANTES, IL-9, Eotaxin, or MIP-1β ([Figure S4](#app2){ref-type="sec"} and data not shown). IL-3, IL-4, IL-5, IL-13, G-CSF, GM-CSF, MCP-1, and MIP-1α were below the detection limit of our assay. IL-10 negatively correlated with the severity of ALI ([Figure S4](#app2){ref-type="sec"}E). In particular, IL-6 levels closely reflected the severity of ALI in resistant *tlr4^−/−^*, *trif^−/−^*, and TRAF6^MC-KO^ mice and injury-prone mice *myd88^−/−^* and *irf3^−/−^* mice ([Figure 2](#fig2){ref-type="fig"}G). To test if IL-6 is indeed involved in the pathogenesis of ALI, we studied *il-6^−/−^* mice ([@bib25]). In response to acid aspiration, *il-6^−/−^* mice exhibited significant improvement of lung function ([Figure 2](#fig2){ref-type="fig"}H), lung edema formation ([Figure S3](#app2){ref-type="sec"}C), and decreased lung pathologies ([Figure 2](#fig2){ref-type="fig"}I). Although these data do not exclude the importance of other cytokines, our genetic results show that loss of IL-6 alleviates the severity of ALI ([Figure 2](#fig2){ref-type="fig"}J).

Oxidative Stress and Formation of Oxidized Phospholipids in ALI {#sec2.4}
---------------------------------------------------------------

Since we used acid aspiration to trigger ALI, a key question emerged: what triggers TLR4 under such injury conditions? To rule out the possibility of LPS contamination, we first treated mice with polymyxin B to neutralize LPS ([@bib21]). Polymyxin B did not alter disease severity in acid-induced ALI ([Figure S5](#app2){ref-type="sec"}A). Moreover, in line with previous data from our group ([@bib20]) and others ([@bib35]), instillation of LPS alone into lungs does not worsen lung function in our acute lung failure model ([Figure S5](#app2){ref-type="sec"}B). We next stimulated alveolar macrophages from WT, *tlr4^−/−^*, *myd88^−/−^*, or *trif^−/−^* mice with bronchoalveolar lavage (BAL) fluid from normal mice (BAL control), BAL fluid from lungs of acid-treated WT mice (BAL acid), or LPS. In line with our genetic data, BAL fluid-induced IL-6 production was mediated via TLR4 and TRIF, but not MyD88 ( [Figure 3](#fig3){ref-type="fig"}A). By contrast, LPS-induced IL-6 production in alveolar macrophages was dependent on TLR4, MyD88, and TRIF ([Figure 3](#fig3){ref-type="fig"}A). Thus, other TLR4-activating agents rather than LPS are generated during the course of ALI.Figure 3Formation of Oxidized Phospholipids in Acute Lung Injury(A) Increase in IL-6 production from baseline in WT, *tlr4*^−/−^, *myd88*^−/−^, and *trif*^−/−^ alveolar macrophages treated with LPS, BAL fluid from normal control, or BAL fluid from acid-treated WT mice. ^∗∗^p \< 0.01. Data are from four separate experiments.(B) Increases in ROS expression in alveolar macrophages obtained from WT mice 60 min after treatment with saline (background control, blue) or acid (white). A representative histogram is shown among five separate experiments.(C) Increased TLR4 surface expression in alveolar macrophages from WT mice treated with saline (control) or acid. Data are from five separate experiments. ^∗^p \< 0.05.(D) Immunohistochemistry for OxPLs detected by the mAb EO6 in lungs of saline-treated control (upper panel) and acid-treated WT mice (lower panel). OxPLs were localized to inflammatory exudates lining the injured alveoli (arrows) in acid-treated lungs. Original magnifications × 400. Lungs were analyzed 3 hr after acid treatment.(E) BAL fluid from acid-treated mice (BAL acid) induces large amounts of IL-6 in WT but not *tlr4*^−/−^ alveolar macrophages. BAL fluid plus an isotype-matched control Ab was compared to BAL fluid plus the mAb EO6. ^∗^p \< 0.05. Data are from four separate experiments.(F) Increase in IL-6 from baseline in peritoneal macrophages isolated from WT and *tlr4*^−/−^ mice in response to nonoxidized PLs or oxidized PLs. ^∗∗^p \< 0.01.(G) Lung elastance in WT mice following intratracheal administration of saline, nonoxidized PLs, and oxidized PLs. n = 4--6 for each group. ^∗∗^p \< 0.01 for the whole time course.(H) Lung elastance in WT and *tlr4*^−/−^ mice following treatment with nonoxidized PLs or oxidized PLs. n = 4 for each group. ^∗∗^p \< 0.01 for the whole time course.Data in (A), (C), and (E)--(H) are mean values ± SEM.

Since the lung air-liquid interface is exposed to the aerobic environment and therefore susceptible to oxidation, we speculated that ALI could result from the local generation of reactive oxygen species (ROS) and the subsequent formation of oxidized phospholipids (OxPLs). We indeed observed induction of ROS in alveolar macrophages following in vivo acid challenge ([Figure 3](#fig3){ref-type="fig"}B). Acid treatment also triggered enhanced TLR4 surface expression ([Figure 3](#fig3){ref-type="fig"}C). To demonstrate the role of OxPLs in vivo we used the well-characterized mAb EO6 ([@bib11]). This mAb specifically detects the phosphocholine (PC) headgroup of phospholipids in which the sn2 side chain has been oxidized but does not recognize native nonoxidized PLs. We observed large amounts of EO6-detectable OxPLs in the BAL fluid of acid-challenged animals ([Figure S5](#app2){ref-type="sec"}C). In situ immunohistochemistry confirmed the generation of EO6-detectable OxPLs in alveolar macrophages as well as inflammatory exudates lining the injured air spaces ([Figure 3](#fig3){ref-type="fig"}D). In addition, we observed formation of the lipid peroxidation breakdown product malondialdehyde detected by the specific mAb MDA2 ([@bib37]) ([Figure S5](#app2){ref-type="sec"}D), further confirming that lipid oxidation does occur in diseased lungs. These data show that acid aspiration triggers the oxidative stress machinery and the generation of OxPLs in lung.

OxPLs Induce Cytokine Production and Acute Lung Injury via TLR4 {#sec2.5}
---------------------------------------------------------------

Minimally modified low-density lipoprotein (LDL) has been previously shown to mediate macrophage activation ([@bib31], [@bib33]) and to modulate the severity of atherosclerosis and inflammatory responses via TLR4 ([@bib31], [@bib30]). To address whether OxPLs generated during ALI can activate innate immune responses, we stimulated WT and *tlr4^−/−^* alveolar macrophages with BAL fluid from normal (BAL control) and diseased lungs (BAL acid). BAL fluid from mice with ALI, which contains OxPLs ([Figure S5](#app2){ref-type="sec"}C), induced large amounts of IL-6 production in WT alveolar macrophages. Neutralization of OxPLs by the specific mAb EO6 attenuated BAL fluid-induced IL-6 production ([Figure 3](#fig3){ref-type="fig"}E). BAL fluid did not trigger IL-6 release in *tlr4^−/−^* alveolar macrophages ([Figure 3](#fig3){ref-type="fig"}E). Similarly, BAL fluid from diseased mice induced IL-6 production in peritoneal ([Figure S6](#app2){ref-type="sec"}A) and bone marrow macrophages ([Figure S6](#app2){ref-type="sec"}B), which was reverted by EO6 Ab treatment. Induction of IL-6 was again dependent on TLR4 expression ([Figures S6](#app2){ref-type="sec"}A and S6B). OxPLs were also observed in acid-treated *trl4^−/−^* mice ([Figure S6](#app2){ref-type="sec"}C).

The major source of PLs in the lung is surfactant, which forms a film at the alveolar air-water interface and reduces surface tension. Surfactant contains 80%--90% PLs including unsaturated phosphatidylcholine that can be oxidized ([@bib41], [@bib47]). In vitro-oxidized surfactant PLs contain EO6-detectable OxPLs ([Figure S6](#app2){ref-type="sec"}D). Addition of purified synthetically oxidized surfactant PLs induced IL-6 production in a dose-dependent manner in WT peritoneal macrophages ([Figure 3](#fig3){ref-type="fig"}F). IL-6 production in response to surfactant OxPLs was decreased by the neutralizing mAb EO6 (data not shown) and dependent on TLR4 expression ([Figure 3](#fig3){ref-type="fig"}F). In line with previous results ([@bib3]), in vivo administration of nonoxidized PLs induces slightly impaired lung function ([Figure 3](#fig3){ref-type="fig"}G). Intratracheal administration of OxPLs markedly worsened lung function in normal mice ([Figure 3](#fig3){ref-type="fig"}G). In a second experimental model, we removed endogenous surfactant via saline lavages, which strongly impairs lung function; we followed this with intratracheal replacement with nonoxidized or oxidized surfactant PLs. In this scenario, challenge with OxPLs resulted in much more severe impairment of lung function and all experimental animals died by 2 hr, whereas mice that received control, nonmodified surfactant PLs stabilized their lung function ([Figure S7](#app2){ref-type="sec"}A). Lung function was comparable among WT and *tlr4^−/−^* mice following administration of nonoxidized surfactant PLs. Loss of TLR4 expression markedly alleviated the severe lung failure phenotype following OxPLs treatment ([Figure 3](#fig3){ref-type="fig"}H). Moreover, administration of OxPLs induced increased levels of IL-6 in the lungs of WT control but not in those of *tlr4^−/−^* mice ([Figure S7](#app2){ref-type="sec"}B). These data indicate that synthetically oxidized surfactant PLs can trigger cytokine production in macrophages and, importantly, acute lung injury in vivo via TLR4.

OxPAPC Triggers Acute Lung Injury {#sec2.6}
---------------------------------

We next attempted to identify specific OxPLs that can trigger ALI via TLR4. The mAb EO6 we used for the detection of OxPLs has been previously reported to specifically bind PC-containing OxPLs such as oxidized 1-palmitoyl-2-arachidonoyl-phosphatidylcholine (OxPAPC) ([Figure S7](#app2){ref-type="sec"}C). We confirmed that the mAB EO6 indeed detects OxPAPC ([Figure S8](#app2){ref-type="sec"}A). To directly test whether OxPAPC can trigger cytokine production via TLR4, we stimulated lung tissue macrophages with OxPAPC and nonoxidized PAPC. Compared to PAPC, OxPAPC induced higher IL-6 levels in WT macrophages, and these levels were attenuated by the neutralizing mAb EO6 ( [Figure 4](#fig4){ref-type="fig"}A). OxPAPC-induced IL-6 production was decreased in *tlr4^−/−^* and *trif^−/−^* lung macrophages, and this residual IL-6 production was not affected by the mAb EO6 ([Figure 4](#fig4){ref-type="fig"}B). Similar to our in vivo experiments, OxPAPC could still trigger IL-6 production in *myd88^−/−^* lung tissue macrophages. LPS-induced IL-6 production in lung macrophages was dependent on TLR4, TRIF, and MyD88 ([Figure 4](#fig4){ref-type="fig"}B). In addition, OxPAPC induced higher IL-6 production than nonoxidized PAPC in alveolar macrophages isolated by lung lavage ([Figure S8](#app2){ref-type="sec"}B). OxPAPC-induced IL-6 production was decreased in *tlr4^−/−^* alveolar macrophages ([Figure S8](#app2){ref-type="sec"}C). Similar to lung macrophages, OxPAPC triggered IL-6 production in peritoneal macrophages dependent on TLR4 and TRIF but not MyD88 ([Figure S8](#app2){ref-type="sec"}D). Thus, OxPAPC can trigger IL-6 production in lung and peritoneal macrophages via TLR4-TRIF signaling. Importantly, intratracheal administration of OxPAPC induced marked deterioration of lung function in WT mice ([Figure 4](#fig4){ref-type="fig"}C). In vivo OxPAPC, but not PAPC, challenges triggered IκBα degradation indicative of an activated NF-κB pathway ([Figure 4](#fig4){ref-type="fig"}D). Moreover, lung function ([Figure 4](#fig4){ref-type="fig"}E) and IL-6 production ([Figure S8](#app2){ref-type="sec"}E) were markedly alleviated in *tlr4^−/−^* and *trif^−/−^* but not *myd88^−/−^* mice. These data indicate that OxPAPC can trigger ALI via TLR4 and TRIF.Figure 4Oxidized PAPC Induces ALI and IL-6 Production via TLR4(A) Increases in IL-6 production from baseline (unstimulated control) in lung tissue macrophages from WT mice in response to PAPC (10 μg/ml) or OxPAPC (10 μg/ml) in the presence of an isotype-matched control mAb or the mAb EO6. ^∗^p \< 0.05 comparing mAb EO6(−). ^∗∗^p \< 0.01 comparing OxPAPC EO6(−) and PAPC EO6(−). Data are from four separate experiments.(B) Increase in IL-6 from baseline (control) in lung tissue macrophages isolated from WT, *tlr4*^−/−^, *myd88*^−/−^, and *trif*^−/−^ mice in response to LPS (1 ng/ml) or OxPAPC (10 μg/ml). ^∗^p \< 0.05 comparing OxPAPC-treated WT or *myd88*^−/−^ macrophages ± EO6. ^∗∗^p \< 0.01 compared to OxPAPC EO6(−) treated WT macrophages. Data are from three separate experiments.(C) Lung elastance in WT mice following intratracheal administration of PAPC or OxPAPC (20 μg/g body weight). n = 4 for each group. ^∗∗^p \< 0.01 for the whole time course.(D) Western blots of IκBα and β-actin in lungs isolated from mice 90 min after saline treatment (control), OxPAPC, or PAPC (20 μg/g body weight). Blots are representative of three separate experiments.(E) Lung elastance at 1.5 hr in WT, *tlr4*^−/−^, *myd88*^−/−^, and *trif*^−/−^ mice following OxPAPC challenge (20 μg/g body weight). The correct genetic background controls are shown. n = 4 for each group. ^∗^p \< 0.05. Data are mean values ± SEM.

Inactivated H5N1 Avian Influenza Virus Can Induce OxPL and ALI in Mice {#sec2.7}
----------------------------------------------------------------------

Patients who died of H5N1 avian influenza or Spanish influenza developed ARDS, and extremely high levels of cytokines have been observed in patients and animals infected with these viruses ([@bib4], [@bib44]). Our data so far showed that acid aspiration triggers production of OxPLs that can augment the severity of ALI and cytokine production via TLR4. We wanted to extend these findings to H5N1-mediated ALI. Inactivated influenza A virus ([@bib29]) or inactivated respiratory syncytial virus ([@bib14]) can induce rapid activation of NF-κB and/or proinflammatory cytokine production in macrophages. The virulence of the 1918 Spanish influenza virus was largely determined by its hemaglutinin (HA), and the recombinant viruses expressing the 1918 viral HA induce high IL-6 production and severe ALI in vivo ([@bib24]). Based on these reports, we tested whether an inactivated H5N1 virus where HA activity is conserved might induce OxPL production and ALI in vivo via TLR4. Since H5N1 subtype influenza A viruses are more potent inducers of cytokines in macrophages than H1N1 subtype influenza ([@bib9]), we used H1N1 as a control.

Pulmonary challenge of inactivated H5N1 avian influenza virus induced rapid impairment of lung function as determined by increased lung elastance ( [Figure 5](#fig5){ref-type="fig"}A), severe edema formation as assessed by wet/dry lung weight ratios ([Figure 5](#fig5){ref-type="fig"}B), and pathological changes such as alveolar wall thickening, bleeding, or the accumulation of inflammatory cells ([Figure S9](#app2){ref-type="sec"}A). Administration of inactivated H1N1 virus had only very mild effects on lung function and lung histology ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S9](#app2){ref-type="sec"}A). In line with a previous study ([@bib45]), we observed influenza A virus nuclear protein-positive cells in the lower respiratory tract (LRT) in mice treated with inactivated H5N1 virus ([Figure 5](#fig5){ref-type="fig"}C). By contrast, we only found very few virus nuclear protein-positive cells in the LRT of H1N1-treated mice ([Figure 5](#fig5){ref-type="fig"}C). Similar to acid treatment, we found higher production of ROS in alveolar macrophages isolated from mice treated with inactivated H5N1 avian influenza virus ([Figure 5](#fig5){ref-type="fig"}D). In addition, TLR4 surface expression was increased in alveolar macrophages from mice treated with inactivated H5N1 ([Figure 5](#fig5){ref-type="fig"}E). In vivo challenge of mice with H1N1 did not result in detectable ROS production or upregulation of TLR4 cell-surface expression ([Figures 5](#fig5){ref-type="fig"}D and 5E). Moreover, we detected OxPLs in the BAL fluid of animals challenged with inactivated H5N1 ([Figure S9](#app2){ref-type="sec"}B). Immunohistochemistry confirmed enhanced generation of EO6-detectable OxPLs at the sites of injury ([Figure S9](#app2){ref-type="sec"}C). We extended the analysis of OxPLs to live H5N1 infections. Similar to inactivated H5N1 ([Figure 5](#fig5){ref-type="fig"}C), influenza virus A protein was detected in the LRT of mice infected with live H5N1 avian influenza virus ([Figure 5](#fig5){ref-type="fig"}F). Importantly, infection with live H5N1 avian influenza virus resulted in the formation of EO6-detectable OxPLs in mouse lung ([Figure 5](#fig5){ref-type="fig"}F). Thus, challenge of mice with H5N1 avian influenza can trigger OxPLs and rapid onset ALI in vivo.Figure 5Inactivated H5N1 Avian Influenza Virus Can Induce OxPLs and ALI in Mice(A) Changes in lung elastance in WT mice following intratracheal administration of vehicle (n = 3), inactivated H1N1 (n = 6), or inactivated H5N1 (n = 8) viruses. ^∗^p \< 0.05 for the whole time course.(B) Lung edema formation 5 hr after vehicle, inactivated H1N1, or inactivated H5N1 treatment. ^∗∗^p \< 0.01.(C) Immunohistochemistry for influenza A nucleoprotein in lung of WT mice challenged with vehicle, inactivated H1N1, or inactivated H5N1 viruses. Influenza A protein-positive cells were present in the lower respiratory tract including alveolar macrophage (arrowhead) and pneumocytes (arrows). Original magnifications × 400.(D) ROS expression in alveolar macrophages from WT mice treated with control vehicle (blue), inactivated H1N1 virus (white, upper panel), or inactivated H5N1 virus (white, lower panel).(E) TLR4 expression in alveolar macrophages from WT mice treated with vehicle (blue), inactivated H1N1 virus (white), or inactivated H5N1 virus (white). Representative histograms are shown for five separate experiments. Data in (D) and (E) are at 1 hr after viral challenge.(F) Immunohistochemistry for influenza A nucleoprotein and EO6-detectable OxPLs in lung of WT mice infected with live H5N1 avian influenza virus. H5N1-infected mice contain large numbers of influenza A protein-positive cells (brown) in the lower respiratory tract (left panels, arrowheads). OxPLs were localized to inflammatory cells (arrowheads) as well as inflammatory exudates (arrow). Lungs were analyzed 4 days after infection. Original magnifications × 100 (upper panels) and × 200 (lower panels). Data are mean values ± SEM.

Inactivated H5N1-Induced ALI Is Attenuated in *tlr4* and *trif* Mutant Mice {#sec2.8}
---------------------------------------------------------------------------

To test whether pulmonary exposure of inactivated H5N1 viruses affects the severity of ALI via the TLR4-TRIF pathway, we analyzed ALI in *tlr4^−/−^* and *trif^−/−^* mice. The *tlr4^−/−^* mice, treated with the inactivated H5N1 virus, showed significantly improved lung elastance ( [Figure 6](#fig6){ref-type="fig"}A), pulmonary edema formation ([Figure 6](#fig6){ref-type="fig"}B), and alleviated lung pathologies ([Figure 6](#fig6){ref-type="fig"}C) compared with control WT mice. Moreover, *trif^−/−^* mice, treated with the inactivated H5N1 virus, showed improved lung elastance ([Figure 6](#fig6){ref-type="fig"}D), pulmonary edema formation ([Figure S9](#app2){ref-type="sec"}D), and alleviated lung pathologies ([Figure 6](#fig6){ref-type="fig"}E). NF-κBp65 activation in macrophages was also impaired in lungs from *tlr4^−/−^* and *trif^−/−^* mice ([Figures 6](#fig6){ref-type="fig"}C and 6E,). In addition, BAL fluid obtained from H5N1-challenged mice induced high levels of IL-6 in WT but not *tlr4^−/−^* alveolar macrophages. Neutralization of OxPLs using the mAb EO6 attenuated IL-6 production in WT but not *tlr4^−/−^* alveolar macrophages ([Figure 6](#fig6){ref-type="fig"}F). Thus, cytokine production in alveolar macrophages and ALI in vivo are attenuated in *tlr4* and *trif* mutant mice in response to challenge with inactivated H5N1 avian influenza virus.Figure 6TLR4- or TRIF-Deficient Mice Show Less Severe ALI to Challenge with Inactivated H5N1 Avian Influenza Virus(A) Lung elastance in WT and *tlr4*^−/−^ mice following administration of vehicle or inactivated H5N1 viruses. n = 5 for each group. ^∗∗^p \< 0.01 for the whole time course.(B) Lung edema formation in WT versus *tlr4*^−/−^ mice 5 hr after H5N1 challenge. ^∗∗^p \< 0.01.(C) Lung pathology (top; H&E staining) and immunolocalization of NFκBp65 (bottom) in lung tissue of H5N1-challenged WT and *tlr4*^−/−^ mice. Note nuclear accumulation of Ser276-phosphorylated NFκBp65 in macrophages from WT lung (red arrows). In H5N1-treated *tlr4*^−/−^ lungs, nuclear NF-κB accumulation was mostly absent from macrophages (green arrows) albeit present in a few cells (red arrow). Original magnifications × 400.(D) Lung elastance in WT and *trif*^−/−^ mice after administration of vehicle or inactivated H5N1 viruses. n = 5 for each group. ^∗∗^p \< 0.01 for the whole time course.(E) Lung pathology (top; H&E staining) and immunolocalization of NFκBp65 (bottom) in lung tissue of H5N1-challenged WT and *trif*^−/−^ mice. Original magnifications × 400.(F) BAL fluid from WT mice 5 hr after a H5N1 challenge (BAL H5N1) triggers IL-6 in WT but not *tlr4*^−/−^ alveolar macrophages. BAL fluid from H5N1-treated mice plus an isotype-matched control mAb (−) was compared to BAL fluid from H5N1-treated mice plus the mAb EO6 (+). ^∗^p \< 0.05. Data are mean values ± SEM.

H5N1 Avian Influenza Virus Triggers Oxidative Stress in Humans {#sec2.9}
--------------------------------------------------------------

Next, we examined whether inactivated H5N1 avian influenza viruses can also trigger the oxidative stress machinery in humans. Stimulation of peripheral blood mononuclear cells (PBMCs) with inactivated H5N1 viruses indeed resulted in generation of ROS ( [Figure 7](#fig7){ref-type="fig"}A). By contrast, challenge with inactivated H1N1 resulted in much less ROS production in human PBMCs. Moreover, FACS staining showed that TLR4 surface expression was upregulated in PBMCs treated with inactivated H5N1 compared to H1N1 ([Figures 7](#fig7){ref-type="fig"}B and [S10](#app2){ref-type="sec"}A). Whereas TLR4 protein is distributed throughout the cytoplasm in human PBMCs under control conditions, challenge of PBMCs with inactivated H5N1 virus induced relocalization and cell membrane association of TLR4 ([Figure 7](#fig7){ref-type="fig"}C). Thus, inactivated H5N1 viruses can induce ROS formation and TLR4 surface expression on primary human monocytes.Figure 7The Oxidative Stress Machinery Controls the Severity of ALI in Response to Inactivated H5N1 Avian Influenza Viruses(A) ROS expression in control PBMCs and PBMCs from the same donor treated with inactivated H1N1 or inactivated H5N1 viruses. Data are from CD14^+^ gated PBMCs. Representative histograms are shown for six separate donors.(B) TLR4 expression in control human PBMCs and H5N1- or H1N1-treated PBMCs. Data are from CD14^+^ gated PBMCs. Representative histograms are shown for six different donors.(C) Immunofluorescence staining of TLR4 in PBMCs treated with formulation control or inactivated H5N1. TLR4 was distributed throughout the cytoplasm in control cells (top). PBMCs treated with inactivated H5N1 showed peripheralization of TLR4 (bottom).(D) Lung elastance in WT and *ncf1*^−/−^ mice following intratracheal administration of inactivated H5N1 viruses. n = 4 for each group. ^∗∗^p \< 0.01 for the whole time course.(E) Lung pathology (top; H&E staining) and immunolocalization of oxidized PLs (bottom) in lung tissue of H5N1-challenged WT and *ncf1*^−/−^ mice. Original magnifications × 200.(F) Immunohistochemistry of OxPLs in lungs from two patients infected with H5N1 avian influenza virus (top) and two patients infected with SARS-coronavirus (bottom).(G) Immunohistochemistry of OxPLs in rhesus monkeys and rabbits infected with Bacillus anthracis (left panels) and Cynomolgus monkeys infected with Monkey Pox or Yersinia pestis (right). In (F) and (G), OxPLs detected by the mAb EO6 were seen in inflammatory exudates lining the injured alveoli (arrows) and macrophages (triangles). Original magnifications × 400. Data are mean values ± SEM.

Loss of NCF1 Improves the Severity of ALI {#sec2.10}
-----------------------------------------

Our data so far showed that inactivated H5N1 viruses can trigger ROS formation in mouse alveolar macrophages and human monocytes. We therefore want to test whether such ROS generation is indeed involved in disease pathogenesis of H5N1 influenza virus-mediated ALI. To address this, we analyzed lung injury in WT and *ncf1* (neutrophil cytosolic factor 1) mutant mice ([@bib19]). Ncf1 is a key component of the NADPH oxidase complex required for oxidative burst and ROS formation ([@bib19]). This *ncf1* mutation affects splicing leading to a near absence of Ncf1 protein ([@bib17]). Interestingly, the *ncf1* mutant mice treated with inactivated H5N1 virus showed significantly improved lung elastance ([Figure 7](#fig7){ref-type="fig"}D), pulmonary edema formation ([Figure S10](#app2){ref-type="sec"}B), and alleviated lung pathologies ([Figure 7](#fig7){ref-type="fig"}E) compared with control mice on the same genetic background. Importantly, in H5N1-challenged *ncf1^−/−^* mice we failed to detect oxidized PL formation ([Figure 7](#fig7){ref-type="fig"}E). Thus, genetic impairment of ROS production results in reduced formation of OxPLs and significantly improved lung functions in response to H5N1 challenge.

Multiple Lethal Lung Pathogens Trigger Formation of OxPLs in Different Species {#sec2.11}
------------------------------------------------------------------------------

Finally, to test whether OxPLs are generated during actual H5N1 influenza virus infections in humans, we analyzed lung samples from two patients who had developed ARDS following H5N1 avian influenza virus infections. Consistent with our mouse acid aspiration and H5N1 models, we detected massive formation of OxPLs localized at the inflammatory exudates lining the injured air spaces as well as alveolar macrophages in the lungs of both H5N1-infected patients ([Figure 7](#fig7){ref-type="fig"}F). Lungs from patients that died of extrapulmonary diseases did not show any detectable OxPL formation ([Figure S10](#app2){ref-type="sec"}C). Thus, H5N1 infections in humans result in the local activation of the oxidative stress machinery and OxPL formation in the lung.

To examine whether OxPL production is a general feature of lethal lung injury that can be seen in different pathogen infections and across wider species barriers, we analyzed lung samples from nine individuals who had developed ARDS following SARS infections. In all SARS-infected human cases tested, we observed marked production of OxPLs in the inflammatory exudates lining the injured air spaces, pneumocytes, as well as alveolar macrophages ([Figure 7](#fig7){ref-type="fig"}F and data not shown). To extend these findings to additional species and pathogens, we analyzed lung samples from animals infected with potential bioterrorism agents. We observed formation of OxPLs in Anthrax-infected Rhesus monkeys, Anthrax-infected rabbits, Monkey Pox-infected Cynomolgus monkeys (Macaca fascicularis), as well as Yersinia pestis-infected Cynomolgus monkeys that developed lung plague ([Figure 7](#fig7){ref-type="fig"}G). By contrast, we could not detect elevated OxPLs in Smallpox or Marburg virus-infected Cynomolgus monkeys, nor in monkeys infected with Western Equine Encephalitis (WEE) or Eastern Equine Encephalitis (EEE) viruses, diseases that did not cause severe lung injury (data not shown). Thus, in multiple species, infections with various lethal lung pathogens such as H5N1 avian influenza virus, SARS-coronavirus, Anthrax, Y. pestis, or Monkey Pox virus can trigger formation of OxPLs in the lung. These results should be extended to additional pathogens and species.

Discussion {#sec3}
==========

Stimulation of TLR4 can trigger the activation of two downstream signaling pathways: MyD88-dependent or TRIF-dependent pathways ([@bib2]). In the classical pathway, MyD88 recruits IL-1R-associated kinase (IRAK) and TRAF6 leading to activation of IKKα/β/γ complexes. TRIF signals through IKK-ɛ leading to activation of IRF3 and the expression of IFN-inducible genes. It has been shown that TRAF6 binds to TRIF though TRAF6-binding motifs in the N-terminal portion of TRIF and is involved in TRIF-mediated activation of NF-κB in vitro ([@bib43]). Importantly, our study shows that innate immune signaling via TLR4-TRIF-TRAF6 is a key genetic pathway that determines the susceptibility to acute lung failure in vivo. Moreover, our bone marrow transplantation experiments and our LysCre TFAF6 mutant mice show that this pathway operates in myeloid cells, in particular lung macrophages. Since macrophages can utilize both TRIF- and MyD88-dependent pathways for cytokine induction, our data might provide an opportunity to minimize ALI via TRIF inhibition while not affecting MyD88-dependent innate immune functions.

Lung has a large surface area that is exposed to the aerobic environment and thus is a highly susceptible site for oxidative events, making the lipids at the air-liquid interface an "ideal" substrate for such lipid modifications. Recently oxidized moieties, including OxPLs, have been implicated as pathogen-associated molecular patterns that are detected by several conserved pattern-recognition receptors ([@bib5], [@bib32]). In particular, minimally oxidized LDL has been found to activate TLR4 on macrophages ([@bib31], [@bib33]), though the exact mechanism of this activation remains elusive. However, this connection has been controversial ([@bib7]). We therefore used a genetic approach to examine whether TLR4 expression is indeed required for OxPL-induced cytokine production in macrophages in vitro or OxPL-induced ALI in vivo. Our genetic data show that OxPL-mediated cytokine release and OxPL-induced ALI depend on TLR4 expression. Thus, OxPLs can either directly or indirectly activate the TLR4 signaling cascade during the course of lung injury. Consistent with previous reports ([@bib40], [@bib26]), we also found that chemical injury and inactivated H5N1 virus upregulate TLR4 surface expression in macrophages. Thus, local lung injury not only triggers activation of the oxidative stress machinery but also induces upregulation of TLR4 involved in the OxPL-induced acute lung injury response.

We have identified OxPAPC as an important trigger of ALI. In fact, OxPAPC has been known to be generated at the sites of inflammation and is found in membranes of apoptotic cells ([@bib8]). Furthermore, OxPAPC can play a proinflammatory role in atherosclerosis ([@bib6], [@bib12]) and impairs the outcome of gram-negative sepsis in vivo ([@bib23]). Interestingly, in the *E. coli*-induced peritonitis model, coadministration of OxPAPC also increased the local production of cytokines, e.g., IL-6 ([@bib23]). On the other hand, anti-inflammatory properties of OxPAPC have been reported in LPS-induced sepsis or ALI, which may be explained by direct antagonism of LPS recognition ([@bib7], [@bib36]). Besides OxPAPC, other OxPLs might also trigger ALI. Moreover, additional TLR4 ligands are also likely to be present, e.g., modified matrix components, dying cells, hyaluronan, or HMGB1 ([@bib34]).

One key question remained, whether oxidative stress is indeed involved in disease pathogenesis of ALI. Our data showed that acid treatment and inactivated H5N1 viruses can trigger ROS formation in mouse alveolar macrophages and human monocytes. Oxidative modifications are also present in all severe lung injuries in all species tested. Of note, gene expression analysis of mice infected with recombinant viruses expressing the 1918 viral HA revealed a high upregulation of ROS-related genes ([@bib22]). We therefore tested H5N1-induced lung injury in *ncf1* mutant mice. Ncf1 encodes one of the activating proteins in the phagocytic NADPH oxidase complex. Importantly, this genetic defect in ROS production resulted in a significantly reduced lung injury in response to challenge with our inactivated H5N1 virus. Moreover, in H5N1-challenged *ncf1* mutant mice we failed to observe EO6-detectable oxidized PLs confirming that Ncf1-regulated oxidative burst is involved in the formation of OxPLs. Thus, activation of the oxidative stress machinery is not simply a by-product of the disease process but controls disease severity.

Our results in two experimental ALI models, acid aspiration and inactivated H5N1-induced ALI, indicate that chemical as well as viral lung pathogens trigger the oxidative stress machinery resulting in ROS generation and the local production of OxPLs. Massive formation of OxPLs occurred in all severe cases of acute lung failure we have analyzed including humans who died of H5N1 or SARS infections and animals that developed lethal lung failure due to Y. pestis, Monkey Pox, pulmonary Anthrax, or H5N1 infections. OxPLs such as OxPAPC can directly trigger cytokine production in macrophages and modulate the severity of acute lung injury in vivo dependent on TLR4-TRIF-TRAF6 expression. Thus, the acute onset of proinflammatory immune responses and severe lung injury caused by different pathogens critically depends on activation of the oxidative stress machinery that couples to innate immunity ([Figure S11](#app2){ref-type="sec"}). Modulation of this injury pathway, therefore, could be utilized to protect patients infected with H5N1 avian influenza virus, SARS-coronavirus, Anthrax, or other as yet unknown lethal lung pathogens from developing acute severe lung failure.

Experimental Procedures {#sec4}
=======================

For detailed Experimental Procedures see the [Supplemental Data](#app2){ref-type="sec"}.

Clinical Patient Profiles {#sec4.1}
-------------------------

Lung samples from two H5N1- and nine SARS-infected humans were used.

Animal Infections {#sec4.2}
-----------------

C57BL6 mice were infected intranasally with live H5N1 avian influenza virus (strain A/HK/483/97) and euthanized for tissue sampling on day 4. Lethal lung infections with Anthrax, Y. pestis, and Monkey Pox virus, as well as infections with Smallpox virus, Marburg virus, WEE, and EEE and lung sampling were performed at the US Army Medical Research Institute of Infectious Diseases.

Mutant Mice {#sec4.3}
-----------

*tlr4, tlr9, myd88*, *tlr3, trif*, *irf3*, *il-6,* and *ncf1* mutant mice have been previously described. Mice harboring a floxed TRAF6 allele will be reported in the future and were crossed onto LysCre mice ([@bib10]). Only sex-, age-, and background-matched mice were used. Basal lung function and lung structure were comparable among all the mice tested.

Acid Aspiration-Induced ALI in Mice {#sec4.4}
-----------------------------------

After intratracheal instillation of HCl (pH = 1.5; 2 ml/kg), animals were ventilated for 3 hr. Total positive end expiratory pressure (*PEEP~t~*) and plateau pressure (*P* ~plat~) were measured at the end of expiratory and inspiratory occlusion. Elastance was calculated as (*P* ~plat~ − *PEEP~t~*) divided by tidal volume (*V* ~T~) every 30 min during the ventilation periods.

Bone Marrow Transplantation {#sec4.5}
---------------------------

Recipient mice were irradiated and 1 × 10^6^ donor bone marrow cells were delivered i.v. through the tail vein. Chimeras were used for experiments 12 weeks after transplantation.

Preparation of Oxidized Surfactant PLs and In Vivo Treatments {#sec4.6}
-------------------------------------------------------------

In vitro oxidation of surfactant PLs was performed according to previously established conditions ([@bib41]). The in vivo impact of nonoxidized surfactant PLs and oxidized surfactant PLs was tested in normal, healthy lung as well as saline-lavaged lungs to remove surfactant.

Polymyxin B, LPS, and OxPAPC Treatment in Mice In Vivo {#sec4.7}
------------------------------------------------------

To neutralize LPS, mice received polymyxin B or control vehicle intratracheally. LPS (*E. coli* O111:B4; 0.5 μg/g body weight), OxPAPC (20 μg/g body weight), or control PAPC (20 μg/g body weight) were instilled intratracheally. Animals were then ventilated for 3 hr and pulmonary elastance determined.

H5N1 Avian Influenza Isolates and H5N1-Induced Lung Injury in Mice {#sec4.8}
------------------------------------------------------------------

Inactivated avian influenza subtypes (H1N1 and A/ck/Yamaguchi/7/04 H5N1) were obtained from the Istituto Zooprofilattico Sperimentale delle Venezie. Vehicle and inactivated H1N1 or H5N1 viruses were instilled intratracheally. Animals were then ventilated for 5 hr and elastance was calculated every 30 min.

Assessment of Blood Oxygenation and Pulmonary Edema {#sec4.9}
---------------------------------------------------

Partial pressure of arterial oxygen (PaO~2~) was measured to assess arterial blood oxygenation as an indicator for respiratory failure. To assess pulmonary edemas, the lung wet/dry weight ratios were calculated.

Histology, In Situ NF-κB Detection, and Immunohistochemistry {#sec4.10}
------------------------------------------------------------

Lung tissue was fixed in 4% buffered formalin. For histological analysis, sections were stained with hematoxylin and eosin (H&E). For detection of activated NFκB, paraffin sections were incubated with a polyclonal anti-phospho-NFκBp65 (Ser276) antibody. Immunohistochemistry to detect oxidized phospholipids (OxPLs) was performed using the mAb EO6 (kindly provided by J.L. Witztum). Immunohistochemistry for influenza A virus nucleoprotein was performed using the HB 65 (EVL anti-influenza NP, subtype A) antibody.

Multiple Cytokine Expression Analyses and Cytokine ELISA {#sec4.11}
--------------------------------------------------------

Frozen lung tissues were homogenized in cell lysis buffer, and supernatants were assayed using multiplex cytokine arrays. For ELISA analyses, supernatants of homogenized lung tissue were assayed using specific kits.

Isolation and Activation of Macrophages {#sec4.12}
---------------------------------------

Bone marrow macrophages were isolated from femurs of 8- to 10-week-old mice. Peritoneal macrophages were obtained by injecting mice with thioglycollate, followed by peritoneal lavage. Alveolar macrophages were obtained from mice by bronchoalveolar lavage (BAL). Lung tissue macrophages were prepared using collagenase and DNase. For measurement of IL-6, macrophages were plated on 96-well plates and stimulated in vitro for 24 hr.

Detection of ROS and TLR4 {#sec4.13}
-------------------------

Mouse alveolar macrophages were obtained from mice treated with vehicle, acid, or inactivated H5N1. Human PBMC were isolated with Ficoll-Hypaque and treated with inactivated H5N1 or H1N1 virus. For ROS detection, cells were incubated with DCF. For mouse TLR4 surface staining, cells were double stained for CD11c and TLR4. For human TLR4 detection, cells were double stained for TLR4 and CD14. ROS and TLR4 expression were assessed by FACS. For TLR4 immunolocalization, PBMCs were fixed, permeabilized, and incubated with anti-TLR4.

Statistical Analyses {#sec4.14}
--------------------

All data are shown as mean ± standard error of the mean (SEM). Measurements at single time points were analyzed by ANOVA and, if significant, further analyzed by a two-tailed t test. Time courses were analyzed by repeated-measurements (mixed model) ANOVA with Bonferroni post-tests.
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